IBO · Impact Biomedical Inc.
Substantial doubt about the company's ability to continue as a going concern.
“As reflected in the accompanying financial statements the Company has incurred operating losses as well as negative cash flows from operating activities over the past two years. These factors raise substantial doubt about the Company's ability to continue as a going concern within one year of the date that the financial statements are issued.”View the 10-Q filed Aug 7, 2026
Income-statement, balance-sheet and cash-flow figures extracted from the company's SEC filings — 10-K annual and 10-Q quarterly reports — and standardised for comparison across periods.
Chart any reported metric, KPI or segment over time — the full statement history lives here
| Line Item | TTM | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|---|
| — | $32K | — | — | $50K | |
| — | $424K | — | — | — | |
| — | -$392K | — | — | — | |
| — | -1225% | — | — | — | |
| $284K | $340K | $278K | $1.69M | $1.23M | |
| $6000 | $24K | $633K | $65K | — | |
| $2.17M | $873K | $718K | $315K | $325K | |
| $1.14M | $1.15M | $1.12M | $1.12M | $1.11M | |
| $28.99M | — | $28.75M | $4.03M | — | |
| — | — | — | $4.03M | $3.45M | |
| -$5.11M | -$4.28M | -$28.75M | -$4.03M | -$3.4M | |
| — | -13381.25% | — | — | -6808% | |
| -$3.97M | -$3.14M | -$27.63M | -$2.91M | -$2.29M | |
| — | $793K | $1.07M | $444K | $462K | |
| — | — | — | $13K | $24K | |
| -$1.8M | -$14.45M | -$24.74M | -$4.41M | -$7.88M | |
| — | -$2.58M | $33K | — | -$621K | |
| $789K | -$11.84M | -$24.71M | -$4.34M | -$7.26M | |
| — | -36993.75% | — | — | -14510% | |
| -$13K | -$32K | -$62K | -$71K | — | |
| $981K | — | — | -$4.34M | -$7.05M | |
| USD/shares | — | -$0.38 | -$2.30 | -$0.07 | -$0.10 |
| USD/shares | — | -$0.38 | -$2.30 | -$0.07 | -$0.10 |
| shares | — | 31.55M | 10.76M | 60.25M | 70.5M |
Price & Valuation
Multiples computed on the strict TTM/EV methodology — today's snapshot against peers, and each ratio recomputed as of past filing dates.
Valuation
Peer medians compare against the 291 similar-size Biotechnology companies (of 533 listed).
Revenue Breakdown
Annual revenue as the company disaggregates it in its own XBRL filings. Years a component wasn't reported show a dash.
Share mode is each component's slice of the reported components that year — issuers rarely tag every revenue dollar, so slices need not sum to total revenue.
By Product & Service (USD)
| Component | FY2025 |
|---|---|
| Biotech Retail Sales | $32,000 |